SHAREHOLDER ALERT: SSL JELD ANAB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / March 30, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Sasol Limited (NYSE:SSL)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/sasol-limited-loss-submission-form?prid=5849&wire=1
Lead Plaintiff Deadline: April 6, 2020
Class Period: March 10, 2015 to January 13, 2020

Allegations against SSL include that: (i) Sasol had conducted insufficient due diligence into, and failed to account for multiple issues with, the Lake Charles Chemicals Project ("LCCP"), as well as the true cost of the project; (ii) construction and operation of the LCCP was consequently plagued by control weaknesses, delays, rising costs, and technical issues; (iii) these issues were exacerbated by Sasol's top-level management, who engaged in improper and unethical behavior with respect to financial reporting for the LCCP and the project's oversight; (iv) all the foregoing was reasonably likely to render the LCCP significantly more expensive than disclosed and negatively impact the Company's financial results; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jeld-Wen Holding, Inc. (NYSE:JELD)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/jeld-wen-holding-inc-loss-submission-form?prid=5849&wire=1
Lead Plaintiff Deadline: April 20, 2020
Class Period: January 26, 2017 to October 15, 2018

Allegations against JELD include that: (1) the Company's products, including doors, did not compete against other manufacturers on price, contrary to Jeld-Wen's representations; (2) the market in which the Company sells its doors is not "highly competitive" as the Company claimed; (3) Jeld-Wen's strong margins and anticipated margin growth were not, as the Company claimed, attributed to changes they had made in Jeld-Wen's business operations and strategies; and (4) Jeld-Wen failed to disclose the Company's anti competitive conduct. Because of the foregoing, Defendants' statements about the Company's business, operations and prospects lacked a reasonable basis.

AnaptysBio, Inc. (NASDAQ:ANAB)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/anaptysbio-inc-loss-submission-form?prid=5849&wire=1
Lead Plaintiff Deadline: May 26, 2020
Class Period: October 10, 2017 to November 7, 2019

Allegations against ANAB include that: (i) AnaptysBio failed to disseminate important data from the Company's Phase 2a trial in atopic dermatitis, including the timing and extent of patients' use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company's statements omitted key information from the Company's Phase 2a trial in peanut allergy, including patients' average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company's decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants' positive statements about the efficacy and prospects of AnaptysBio's lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 583112